What Is Moleculin Biotech, Inc. (MBRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Moleculin Biotech, Inc.'s intrinsic value is estimated at a composite fair value of $4.54. At a current market price of $2.31, 6 of 7 active valuation models identify upside potential, projecting an average implied return of +96.4%. Notably, Dynamic NAV sees the most upside at +191.9% (fair value: $6.74), while Bayesian DCF is the most conservative at -22.2% ($1.80). The spread between these extremes — +214.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About MBRX?
7 of 13 models are currently active for MBRX. Of these, 6 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates MBRX's intrinsic value at $1.80, implying -22.2% downside from the current price. See which stocks rank higher →
How Does MBRX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, MBRX ranks #326 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Moleculin Biotech, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating MBRX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is MBRX a Value Trap?
CirclFi's Value Trap algorithm assigns MBRX a score of 39/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Moleculin Biotech, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Moleculin Biotech, Inc.'s fundamental quality profile registers 4.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +214.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MBRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MBRX's 7 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad